About this medicine

Memantine is a medicine for Alzheimer's dementia symptoms, not a cure. UK Ebixa tablets and measured liquid use once-daily dosing. US extended-release strengths, twice-daily schedules and fixed combinations are not interchangeable instructions for the products described here.

What is this medicine used for?

The checked licence covers adults with moderate to severe Alzheimer's disease. NICE recommends it alone in severe disease or moderate disease when cholinesterase inhibitors are unsuitable, and describes adding it to an existing cholinesterase inhibitor at specified stages. This does not establish a licence for every dementia or developmental condition.

Which warning signs need help?

Severe allergy, collapse, seizure or trouble breathing needs urgent medical help. New severe confusion, marked drowsiness or suspected overdose also warrants prompt assessment. Do not wait for symptoms to become severe, and use emergency services in the country where the person actually is.

How do I take it safely?

The Ebixa reference schedule starts at 5 mg once daily and increases by 5 mg at weekly intervals to 20 mg/day if appropriate. The scored 10 mg tablet can provide a 5 mg half. This is product information, not permission to titrate without the prescriber.

For the pump liquid, follow its initial priming instructions and use only its supplied bottle and pump. One complete actuation delivers 5 mg, not 1 ml. The sorbitol-containing solution is unsuitable in hereditary fructose intolerance; another formulation needs separate assessment.

What side effects should I know about?

Headache, dizziness, balance difficulty, sleepiness, constipation and raised blood pressure are recognised effects. Tell the team about persistent symptoms, hallucinations, new falls or loss of function. A suspected adverse effect can be reported through the MHRA Yellow Card system as well as discussed clinically.

Who needs extra care with this medicine?

Kidney function affects dosing: the checked SmPC uses 10 mg/day in severe renal impairment and initially in moderate impairment, with a carefully assessed increase possible in the latter. Severe hepatic impairment is not recommended. Seizures, recent heart attack, uncontrolled hypertension and heart failure require particular review.

Can it affect my other medicines?

Avoid combining with other NMDA antagonists such as amantadine, ketamine or dextromethorphan without specialist assessment. Other interactions involve dopaminergic medicines, anticholinergics, baclofen and dantrolene. Warfarin users may need closer INR monitoring. Limited CYP metabolism does not make the medicine interaction-free.

What check-ups will I need?

Assess kidney function, tolerability, cognitive and daily-function benefit, and whether medicines are actually taken correctly. The SmPC recommends reassessment preferably within three months of starting, then regularly. Caregiver observations can identify duplicate doses, falls or a change in behaviour that a brief appointment may miss.

What about pregnancy, breastfeeding and age?

Memantine is not recommended for under-18s in the checked product leaflet. Pregnancy and breastfeeding need individual discussion because information is limited; NHS advice says it is not usually recommended. In older adults, organ function, tolerability and practical support matter more than age alone.

What if I miss a dose or want to stop?

Skip a missed dose and take the next at the usual time; never double. Ask for advice after a longer interruption rather than guessing a restart regimen. Discuss stopping with the team so benefit and adverse effects can be reassessed. The pump must not be aimed directly into the mouth.

How does it work?

Memantine acts at NMDA receptors, proteins that receive messages from glutamate, a chemical messenger used by brain cells. These receptors control tiny channels that allow electrically charged particles to move into or out of a cell, influencing its response. Glutamate normally supports communication involved in learning and memory, while sustained excessive activation has been proposed as one contributor to symptoms.

Memantine can block the channel after it opens, reducing movement through it. This is different from the action of donepezil, galantamine or rivastigmine, which increase the availability of another messenger, acetylcholine, by slowing its breakdown. The full link between memantine’s channel action and symptom benefit remains uncertain, and it has not been shown to stop the underlying loss of nerve cells.

How does it affect my body?

Treatment can affect alertness, balance and bowel function as well as cognition. Dizziness and constipation can matter greatly to someone already vulnerable to falls or reduced independence. Review new symptoms with the care team, including possible illness or other medicines, rather than automatically attributing everything to dementia.

How does my body process it?

Memantine has a long elimination half-life, around 60–100 hours in the checked UK information. Renal elimination is important and CYP metabolism relatively limited. Alkaline urine can markedly slow clearance, so severe urinary infection, renal conditions or major dietary changes may alter exposure.

How do treatment options differ?

Unlike cholinesterase inhibitors, memantine acts on NMDA signalling. NICE's choices depend partly on Alzheimer's severity and tolerance of other treatments; these mechanisms are not a simple ranking. A UK treatment recommendation also does not establish identical access in all four NHS systems.

A closer look at the science

It is a voltage-dependent, moderate-affinity, uncompetitive NMDA antagonist. In plain language, its block depends on channel activity and electrical conditions. It is not a blanket removal of glutamate from the brain, and the molecular explanation alone cannot predict the degree of symptom benefit.

How was this medicine developed?

The checked Ebixa UK product record dates from January 2021; this is the recorded regulatory version, not memantine's discovery date or first worldwide use. NHS information reviewed in August 2026 remains separately dated. Current retrieval does not turn an older SmPC revision into a new revision.

Sources and References

  1. Ebixa 10 mg film-coated tablets: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  2. Ebixa 5 mg/pump actuation oral solution: SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  3. Ebixa 5 mg/pump actuation oral solution: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  4. NHS: Memantine

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  5. NICE NG97: Dementia recommendations

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  6. NICE TA217: What has NICE said?

    Scope: United Kingdom; NHS/NICE implementation varies by nation.

  7. Memantine hydrochloride immediate-release tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  8. Memantine hydrochloride extended-release capsules: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  9. Memantine: MedlinePlus Drug Information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?; How should this medicine be used?. This does not establish UK product authorisation or prescribing..

  10. Schizophrenia
  11. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top